4
$VRTX · Vertex Pharmaceuticals Incorporated
AI overview
This SEC Form 4 filing reports a change in beneficial ownership by Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals Incorporated. According to the filing, Dr. Bhatia sold 271 shares of Vertex common stock on November 16, 2026, at a price of $547.86 per share. After the transaction, she directly held 4,653 shares of common stock.
The filing indicates that the sale was made pursuant to a company-approved trading plan under Rule 10b5-1, which Dr. Bhatia entered into on August 13, 2026. The form was signed on November 18, 2026, by an attorney-in-fact on her behalf.
Related & recent SEC filings